Zynlonta (loncastuximab tesirine-lpyl)

Adult Dosing .

Dosage forms:  INJ

Special Note

[formulation clarification]

Info: nonproprietary name = loncastuximab tesirine-lpyl

[uses, dosing may vary]

Info: refer to institution protocols and pkg insert prior to prescribing for uses, premeds, and dosing incl. toxicity-related dose adjustments

large B-cell lymphoma, relapsed or refractory

[0.15 mg/kg/dose IV x1 on day 1 of 21-day cycle x2 cycles, then 0.075 mg/kg/dose IV x1 on day 1 of 21-day cycle starting cycle 3 until dz progression]

Info: use adjusted wt = [35 kg/m^2 x (height in meters)^2] to calculate dose if BMI 35 kg/m^2 or greater; for pts w/ diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from low-grade lymphoma, or high-grade B-cell lymphoma who have received at least 2 lines of tx

renal dosing

[see below]

CrCl >30: no adjustment; CrCl <30: not defined

HD/PD: not defined

hepatic dosing

[see below]

bilirubin 1.1-1.5x ULN or AST >ULN: no adjustment; bilirubin >1.5x ULN: not defined

Peds Dosing .

Peds dosing is currently unavailable or not applicable for this drug.